Start Submission Become a Reviewer

Reading: New Agents to Prevent Strokes in Nonvalvular Atrial Fibrillation

Download

A- A+
Alt. Display

Editorials

New Agents to Prevent Strokes in Nonvalvular Atrial Fibrillation

Authors:

David Putney ,

Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas, US
About David
Pharm.D.
X close

Craig Pratt

Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas, US
About Craig
M.D.
X close

Abstract

Introduction

Anticoagulation for atrial fibrillation has been dependant on warfarin for the past 30 years. However, the recent FDA approvals of dabigatran and rivaroxaban and the expected approval for apixaban have provided several new alternatives for our patients. Many factors must be considered when selecting the most appropriate agent for preventing stroke in nonvalvular atrial fibrillation. The following trials have provided the foundation for decision making when considering alternatives to warfarin therapy.

How to Cite: 1. Putney D, Pratt C. New Agents to Prevent Strokes in Nonvalvular Atrial Fibrillation. Methodist DeBakey Cardiovascular Journal. 2012;8(3):44-46. DOI: http://doi.org/10.14797/mdcj-8-3-44
Published on 01 Jul 2012.

Downloads

  • PDF (EN)